Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue was flat, EPS fell 296.0%, free cash flow grew 121.4% and total debt fell 3.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

41.52 0.41 +1.00%
Market cap
$47.9B
P/E
65.9×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
17,258.00 16,544.00 15,846.00 14,925.00 15,878.00 16,659.00 16,887.00 18,271.00 22,385.00 21,903.00
Revenue Growth
4.32% 4.40% 6.17% (6.00%) (4.69%) (1.35%) (7.57%) (18.38%) 2.20% 11.45%
Gross Profit
8,938.00 8,063.00 7,646.00 6,973.00 7,594.00 7,726.00 7,536.00 8,296.00 10,615.00 11,859.00
Operating Income
2,158.00 977.00 433.00 (2,197.00) 1,715.00 (3,571.00) (444.00) 1,390.00 (17,484.00) 2,154.00
EBT
1,223.00 (1,284.00) (624.00) (3,163.00) 658.00 (4,406.00) (1,265.00) (2,596.00) (18,379.00) 824.00
Income after Tax
1,403.00 (1,960.00) (617.00) (2,520.00) 447.00 (4,238.00) (987.00) (2,401.00) (16,446.00) 303.00
Net Income Common
1,410.00 (1,639.00) (559.00) (2,446.00) 417.00 (3,990.00) (999.00) (2,399.00) (16,525.00) 68.00
EPS (Diluted)
1.21 (1.45) (0.50) (2.12) 0.38 (3.64) (0.91) (2.35) (16.26) 0.07
Shares (Diluted, Weighted)
1,163.00 1,131.00 1,119.00 1,110.00 1,107.00 1,095.00 1,091.00 1,021.00 1,016.00 961.00
Gross Margin
51.79% 48.74% 48.25% 46.72% 47.83% 46.38% 44.63% 45.41% 47.42% 54.14%
EBIT Margin
12.50% 5.91% 2.73% (14.72%) 10.80% (21.44%) (2.63%) 7.61% (78.11%) 9.83%
Net Profit Margin
8.17% (9.91%) (3.53%) (16.39%) 2.63% (23.95%) (5.92%) (13.13%) (73.82%) 0.31%
Free Cash Flow Margin
6.85% 4.79% 5.74% 7.44% 3.45% 4.23% 3.35% 14.70% 21.57% 28.88%
EBITDA
3,160.00 2,036.00 1,586.00 (889.00) 3,045.00 (2,014.00) 1,278.00 3,232.00 (15,372.00) 3,678.00
EBIT
2,158.00 977.00 433.00 (2,197.00) 1,715.00 (3,571.00) (444.00) 1,390.00 (17,484.00) 2,154.00

Show all line items

In millions of $ except per-share values · columns are period end dates